SPARQL
Query
Update
Search
Quick
Advanced
Co-occurrence
RelFinder
About
Sources
Admin
System Info
Repository Management
Search Configuration
Sources
19700194
Source:
http://linkedlifedata.com/resource/pubmed/id/19700194
Search
Subject
(
64
)
Predicate
Object
All
Download in:
JSON
RDF
N3/Turtle
N-Triples
Switch to
Custom View
Named Graph
All
UniProt
NCBIGene
DrugBank
ClinicalTrials
UMLS
PubMed
Mappings
MentionedEntities
Language
All
English
Español
Português
Français
Deutsch
Русский
日本語
Български
Inference
Explicit and implicit
Explicit only
Implicit only
Statements in which the resource exists as a subject.
Predicate
Object
rdf:type
pubmed:Citation
lifeskim:mentions
umls-concept:C0011847
,
umls-concept:C0013604
,
umls-concept:C0205225
,
umls-concept:C0439231
,
umls-concept:C0450295
,
umls-concept:C1274040
,
umls-concept:C1566537
,
umls-concept:C2349179
,
umls-concept:C2603343
pubmed:issue
11
pubmed:dateCreated
2009-11-3
pubmed:abstractText
To compare ranibizumab with focal/grid laser or a combination of both in diabetic macular edema (DME).
pubmed:grant
http://linkedlifedata.com/resource/pubmed/grant/R01 EY017577-02
pubmed:language
eng
pubmed:journal
http://linkedlifedata.com/resource/pubmed/journal/7802443
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal
,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized
,
http://linkedlifedata.com/resource/pubmed/chemical/ranibizumab
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1549-4713
pubmed:author
pubmed-author:AbrahamPremaP
,
pubmed-author:BoyerDavidD
,
pubmed-author:CampochiaroPeter APA
,
pubmed-author:DoDiana VDV
,
pubmed-author:HeierJeffery SJS
,
pubmed-author:LimJenniferJ
,
pubmed-author:NguyenQuan DongQD
,
pubmed-author:READ-2 Study Group
,
pubmed-author:ShahSyed MahmoodSM
pubmed:issnType
Electronic
pubmed:volume
116
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2175-81.e1
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:19700194-Antibodies, Monoclonal
,
pubmed-meshheading:19700194-Antibodies, Monoclonal, Humanized
,
pubmed-meshheading:19700194-Combined Modality Therapy
,
pubmed-meshheading:19700194-Diabetic Retinopathy
,
pubmed-meshheading:19700194-Endpoint Determination
,
pubmed-meshheading:19700194-Female
,
pubmed-meshheading:19700194-Humans
,
pubmed-meshheading:19700194-Injections
,
pubmed-meshheading:19700194-Laser Coagulation
,
pubmed-meshheading:19700194-Macular Edema
,
pubmed-meshheading:19700194-Male
,
pubmed-meshheading:19700194-Middle Aged
,
pubmed-meshheading:19700194-Prospective Studies
,
pubmed-meshheading:19700194-Tomography, Optical Coherence
,
pubmed-meshheading:19700194-Treatment Outcome
,
pubmed-meshheading:19700194-Visual Acuity
,
pubmed-meshheading:19700194-Vitreous Body
pubmed:year
2009
pubmed:articleTitle
Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study.
pubmed:affiliation
Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-9277, USA.
pubmed:publicationType
Journal Article
,
Comparative Study
,
Randomized Controlled Trial
,
Research Support, Non-U.S. Gov't
,
Multicenter Study
,
Clinical Trial, Phase II